MA55624A - Composés, compositions et procédés - Google Patents
Composés, compositions et procédésInfo
- Publication number
- MA55624A MA55624A MA055624A MA55624A MA55624A MA 55624 A MA55624 A MA 55624A MA 055624 A MA055624 A MA 055624A MA 55624 A MA55624 A MA 55624A MA 55624 A MA55624 A MA 55624A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- compounds
- methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832775P | 2019-04-11 | 2019-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55624A true MA55624A (fr) | 2022-02-16 |
Family
ID=72752101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055624A MA55624A (fr) | 2019-04-11 | 2020-04-10 | Composés, compositions et procédés |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12358896B2 (https=) |
| EP (1) | EP3953348B1 (https=) |
| JP (1) | JP7623294B2 (https=) |
| KR (1) | KR20210151887A (https=) |
| CN (1) | CN113939294A (https=) |
| AR (1) | AR118641A1 (https=) |
| AU (1) | AU2020272045B2 (https=) |
| BR (1) | BR112021020027A2 (https=) |
| CA (1) | CA3136447A1 (https=) |
| DK (1) | DK3953348T3 (https=) |
| EA (1) | EA202192530A1 (https=) |
| ES (1) | ES3018383T3 (https=) |
| IL (1) | IL287120B2 (https=) |
| MA (1) | MA55624A (https=) |
| MX (1) | MX2021012392A (https=) |
| SG (1) | SG11202111058XA (https=) |
| TW (1) | TWI851710B (https=) |
| WO (1) | WO2020210684A1 (https=) |
| ZA (1) | ZA202107499B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112088003B (zh) | 2017-12-20 | 2023-10-13 | 戴纳立制药公司 | 制备嘧啶基-4-氨基吡唑化合物的工艺 |
| EP4238975A4 (en) * | 2020-10-29 | 2024-06-12 | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | SUBSTITUTED DIARYLAMINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, MANUFACTURING PROCESS THEREOF AND USE THEREOF |
| CN116120291B (zh) * | 2023-04-11 | 2023-06-30 | 英矽智能科技(上海)有限公司 | 吲唑类化合物及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2638031T3 (https=) | 2010-11-10 | 2018-03-10 | ||
| SMT202100699T1 (it) | 2016-06-16 | 2022-01-10 | Denali Therapeutics Inc | Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi |
| WO2018217946A1 (en) | 2017-05-24 | 2018-11-29 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CN112088003B (zh) | 2017-12-20 | 2023-10-13 | 戴纳立制药公司 | 制备嘧啶基-4-氨基吡唑化合物的工艺 |
-
2020
- 2020-04-08 AR ARP200101008A patent/AR118641A1/es unknown
- 2020-04-10 US US17/602,480 patent/US12358896B2/en active Active
- 2020-04-10 SG SG11202111058XA patent/SG11202111058XA/en unknown
- 2020-04-10 CN CN202080041217.0A patent/CN113939294A/zh active Pending
- 2020-04-10 IL IL287120A patent/IL287120B2/en unknown
- 2020-04-10 JP JP2021559818A patent/JP7623294B2/ja active Active
- 2020-04-10 TW TW109112173A patent/TWI851710B/zh active
- 2020-04-10 EP EP20787582.4A patent/EP3953348B1/en active Active
- 2020-04-10 ES ES20787582T patent/ES3018383T3/es active Active
- 2020-04-10 WO PCT/US2020/027742 patent/WO2020210684A1/en not_active Ceased
- 2020-04-10 CA CA3136447A patent/CA3136447A1/en active Pending
- 2020-04-10 DK DK20787582.4T patent/DK3953348T3/da active
- 2020-04-10 MX MX2021012392A patent/MX2021012392A/es unknown
- 2020-04-10 MA MA055624A patent/MA55624A/fr unknown
- 2020-04-10 BR BR112021020027A patent/BR112021020027A2/pt unknown
- 2020-04-10 KR KR1020217036412A patent/KR20210151887A/ko active Pending
- 2020-04-10 AU AU2020272045A patent/AU2020272045B2/en active Active
- 2020-04-10 EA EA202192530A patent/EA202192530A1/ru unknown
-
2021
- 2021-10-05 ZA ZA2021/07499A patent/ZA202107499B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3953348A1 (en) | 2022-02-16 |
| CN113939294A (zh) | 2022-01-14 |
| TWI851710B (zh) | 2024-08-11 |
| EP3953348B1 (en) | 2024-12-18 |
| ZA202107499B (en) | 2022-06-29 |
| JP2022526015A (ja) | 2022-05-20 |
| ES3018383T3 (es) | 2025-05-16 |
| JP7623294B2 (ja) | 2025-01-28 |
| CA3136447A1 (en) | 2020-10-15 |
| SG11202111058XA (en) | 2021-11-29 |
| IL287120B1 (en) | 2025-02-01 |
| EP3953348A4 (en) | 2023-01-18 |
| TW202104213A (zh) | 2021-02-01 |
| EA202192530A1 (ru) | 2022-03-15 |
| AR118641A1 (es) | 2021-10-20 |
| WO2020210684A1 (en) | 2020-10-15 |
| AU2020272045B2 (en) | 2026-01-15 |
| KR20210151887A (ko) | 2021-12-14 |
| IL287120B2 (en) | 2025-06-01 |
| AU2020272045A1 (en) | 2021-10-28 |
| MX2021012392A (es) | 2021-11-12 |
| US12358896B2 (en) | 2025-07-15 |
| US20220220094A1 (en) | 2022-07-14 |
| IL287120A (en) | 2021-12-01 |
| DK3953348T3 (da) | 2025-03-17 |
| BR112021020027A2 (pt) | 2021-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3923935A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS | |
| MA54959A (fr) | Composés, compositions et procédés | |
| MA49858A (fr) | Composés, compositions et procédés | |
| MA54946A (fr) | Procédés et composés | |
| EP3917927A4 (en) | IMMUNE MODULATORS, COMPOSITIONS AND METHODS THEREOF | |
| MA50063A (fr) | Composés, compositions et procédés | |
| MA54875A (fr) | Compositions oligonucléotidiques et procédés associés | |
| EP3823673A4 (en) | ANTI-CD112R COMPOSITIONS AND METHODS | |
| EP3806906A4 (en) | KETOGENIC COMPOUNDS, COMPOSITIONS, PROCESSES AND THEIR USE | |
| EP3380101A4 (en) | EIF4-A-INHIBITING COMPOUNDS AND METHODS THEREFOR | |
| EP3880194A4 (en) | DEUTERED COMPOUNDS, COMPOSITIONS AND USES | |
| MA56032A (fr) | Composés, compositions et procédés d'utilisation | |
| LT4084779T (lt) | 1-(4-brom-5-(1-etil-7-(metilamino)-2-okso-1,2-dihidro-1,6-naftiridin-3-il) -2- fluorfenil)-3-fenilkarbamido kompozicijos | |
| DK3924443T3 (da) | Compositions | |
| EP3494119A4 (en) | CONNECTIONS AND COMPOSITIONS AND USES THEREOF | |
| MA52896A (fr) | Composés inhibiteurs de vmat2, compositions et méthodes associées | |
| MA48942A (fr) | Composés thérapeutiques, compositions et procédés d'utilisation associés | |
| PL3967726T3 (pl) | Kompozycja utwardzalna | |
| EP3871694A4 (en) | COMPOSITION | |
| EP4077318A4 (en) | Compounds | |
| EP4079787A4 (en) | CURDABLE COMPOSITION | |
| EP3552017A4 (en) | CONNECTIONS, COMPOSITIONS AND METHODS | |
| EP3981256A4 (en) | COMPOSITION | |
| EP3801021A4 (en) | SPORICIDAL METHODS AND COMPOSITIONS | |
| EP4079785A4 (en) | Curable composition |